RCKT ROCKET PHARMACEUTICALS, INC.

8-K Current Report

Filed: March 10, 2026

Health Care

Pharmaceutical Preparations

ROCKET PHARMACEUTICALS, INC. (RCKT) 8-K current report filed with SEC EDGAR on March 10, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• ATM offering up to $100M in common stock via Cantor Fitzgerald, filed March 10, 2026 under existing S-3 shelf registration
• Sales agent commission up to 3.0% of gross proceeds — maximum dilution cost ~$3M if fully drawn

+3 more insights

Item 1.02 · Termination of a Material Definitive Agreement

• Rocket Pharma terminated its prior ATM agreement with Cowen and Company (TD Securities affiliate), originally dated Feb 28, 2022
• Termination triggered by entry into a new Sales Agreement, signaling a change in ATM program counterparty or structure

+1 more insights

Other ROCKET PHARMACEUTICALS, INC. 8-K Filings

8-K Feb 26, 2026

Get deeper insights on ROCKET PHARMACEUTICALS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.